Nuclea Nabs $3.4M Deal

Luke Timmerman10/22/09

Nuclea Biotechnologies, the Pittsfield, MA-based developer of genomic tests for cancer research, has raised $3.4 million in new equity financing, according to a regulatory filing. The company, which says on its website that it has collaborations with the Dana-Farber Cancer Institute in Boston and the Johns Hopkins School of Medicine in Baltimore, is seeking to discover genomic signatures that could lead to better diagnosis and prognosis for cancer patients. The company said in July it has closed on a $1 million private placement.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.